Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
This transaction is the third acquisition by three different Japanese players in this segment
The pooled prevalence of GERD in the Indian population is 15.6 %
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Subscribe To Our Newsletter & Stay Updated